1
1 of 2
- Yale Alzheimer's Disease Research Unit1 Church StreetSte 8th FloorNew Haven, CT 06510
- Adler Geriatric Assessment Center874 Howard AvenueNew Haven, CT 06519
Christopher van Dyck, MD
Geriatric Psychiatry, Memory Disorders & Cognitive Neurology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Geriatric Psychiatry and Psychiatry
Titles
- Professor of Psychiatry, Neurology, and Neuroscience
- Director, Alzheimer's Disease Research Unit
- Director, Yale Alzheimer's Disease Research Center
- Director, Division of Aging and Geriatric Psychiatry
Education & Training
- MDNorthwestern University (1984)
- BAYale University (1978)
- ResidentYale-New Haven Hospital
- FellowYale University School of Medicine
Languages Spoken
- English
- Français (French)
Additional Information
Honors & Recognitions
- “Leader in Advancing Research” Award: Alzheimer’s Association (2017)
- Best Doctors in New York (Top 2%), as Featured in New York Magazine: Castle Connolly (2005), (2014)
- “Compassion and Cure” Award: Alzheimer’s Association (2005)
- Junior Investigator Award: American Association for Geriatric Psychiatry (1996)
Board Certifications
- AB of Psychiatry & Neurology, Psychiatry (1991)
Publications
- Datta D, Perone I, Wijegunawardana D, Liang F, Morozov Y, Arellano J, Duque A, Xie Z, van Dyck C, Joyce M, Arnsten A. Nanoscale imaging of pT217‐tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early‐stage neurodegeneration. Alzheimer's & Dementia 2024 PMID: 38445818, DOI: 10.1002/alz.13737.
- Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.
- Wang G, Li Y, Xiong C, Benzinger T, Gordon B, Hassenstab J, Aschenbrenner A, McDade E, Clifford D, Libre‐Guerra J, Shi X, Mummery C, van Dyck C, Lah J, Honig L, Day G, Ringman J, Brooks W, Fox N, Suzuki K, Levin J, Jucker M, Delmar P, Bittner T, Bateman R, Team F. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease. Alzheimer's & Dementia 2024 PMID: 38400532, DOI: 10.1002/alz.13735.
- van Dyck C, Mecca A, O’Dell R, Bartlett H, Diepenbrock N, Huang Y, Hamby M, Grundman M, Catalano S, Caggiano A, Carson R. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease. Alzheimer's Research & Therapy 2024, 16: 20. PMID: 38273408, PMCID: PMC10809445, DOI: 10.1186/s13195-024-01382-2.
- Trainer A, Xu W, Chase A, O'Dell R, Tun S, Li J, Ju S, van Dyck C, Mecca A, Fredricks C. Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079435.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. Anatomical characterization of pT217‐tau in aged rhesus macaque association cortices: Relevance for trans‐synaptic propagation in sporadic Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.075998.
- Tumati S, Vieira D, Bawa K, Andreazza A, Mintzer J, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Herrmann N, Lanctôt K. Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079161.
- Young J, Park H, Kim M, Par-Young J, Bartlett H, Kim H, Unlu S, Osmani L, Shin M, Bucala R, van Dyck C, Allore H, Mecca A, You S, Kang I. Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease. Immunity & Ageing 2023, 20: 71. PMID: 38042785, PMCID: PMC10693128, DOI: 10.1186/s12979-023-00396-y.
- Toyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot J, Matuskey D, Mecca A, Pittman B, Dias M, Nabulsi N, Finnema S, Chen M, Arnsten A, Radhakrishnan R, Skosnik P, D’Souza D, Esterlis I, Huang Y, van Dyck C, Carson R. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 51: 1012-1022. PMID: 37955791, DOI: 10.1007/s00259-023-06487-8.
- Bathla S, Datta D, Liang F, Barthelemy N, Wiseman R, Slusher B, Asher J, Zeiss C, Ekanayake‐Alper D, Holden D, Terwilliger G, Duque A, Arellano J, van Dyck C, Bateman R, Xie Z, Nairn A, Arnsten A. Chronic GCPII (glutamate‐carboxypeptidase‐II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaques. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12431. PMID: 37915375, PMCID: PMC10617575, DOI: 10.1002/trc2.12431.
- Datta D, Perone I, Morozov Y, Arellano J, Duque A, Rakic P, van Dyck C, Arnsten A. Localization of PDE4D, HCN1 channels, and mGluR3 in rhesus macaque entorhinal cortex may confer vulnerability in Alzheimer’s disease. Cerebral Cortex 2023, 33: 11501-11516. PMID: 37874022, PMCID: PMC10724870, DOI: 10.1093/cercor/bhad382.
- Miller A, Mecca A, Sharp E, van Dyck C, O'Dell R. Hearing Loss is Associated with Faster Cognitive Decline but not Diagnostic Conversion in the ADNI Cohort. American Journal Of Geriatric Psychiatry 2023, 31: e19-e20. DOI: 10.1016/j.jagp.2023.02.027.
- Silva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Varma P, Toyonaga T, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET. American Journal Of Geriatric Psychiatry 2023, 32: 17-28. PMID: 37673749, PMCID: PMC10840732, DOI: 10.1016/j.jagp.2023.08.002.
- Sperling R, Donohue M, Raman R, Rafii M, Johnson K, Masters C, van Dyck C, Iwatsubo T, Marshall G, Yaari R, Mancini M, Holdridge K, Case M, Sims J, Aisen P. Trial of Solanezumab in Preclinical Alzheimer’s Disease. New England Journal Of Medicine 2023, 389: 1096-1107. PMID: 37458272, PMCID: PMC10559996, DOI: 10.1056/nejmoa2305032.
- O'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Ni G, Chupak A, Zhao W, Salardini E, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease. NeuroImage Clinical 2023, 39: 103457. PMID: 37422964, PMCID: PMC10338149, DOI: 10.1016/j.nicl.2023.103457.
- Lanctôt K, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg P, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Padala K, Herrmann N. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. American Journal Of Geriatric Psychiatry 2023, 31: 1077-1087. PMID: 37385898, PMCID: PMC10765607, DOI: 10.1016/j.jagp.2023.06.002.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. 557. Nanoscale Imaging of pT217-Tau in Aged Rhesus Macaque: Trans-Synaptic Propagation and Seeding of Tau Pathology in Entorhinal Cortex. Biological Psychiatry 2023, 93: s319. DOI: 10.1016/j.biopsych.2023.02.797.
- van Dyck C, Sabbagh M, Cohen S. Lecanemab in Early Alzheimer's Disease. Reply. New England Journal Of Medicine 2023, 388: 1631-1632. PMID: 37099355, DOI: 10.1056/nejmc2301380.
- Lanctôt K, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2023, 35: 664-672. PMID: 37066690, PMCID: PMC10579450, DOI: 10.1017/s1041610223000327.
- Chen C, McCullough A, Gordon B, Joseph-Mathurin N, Flores S, McKay N, Hobbs D, Hornbeck R, Fagan A, Cruchaga C, Goate A, Perrin R, Wang G, Li Y, Shi X, Xiong C, Pontecorvo M, Klein G, Su Y, Klunk W, Jack C, Koeppe R, Snider B, Berman S, Roberson E, Brosch J, Surti G, Jiménez-Velázquez I, Galasko D, Honig L, Brooks W, Clarnette R, Wallon D, Dubois B, Pariente J, Pasquier F, Sanchez-Valle R, Shcherbinin S, Higgins I, Tunali I, Masters C, van Dyck C, Masellis M, Hsiung R, Gauthier S, Salloway S, Clifford D, Mills S, Supnet-Bell C, McDade E, Bateman R, Benzinger T. Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 50: 2669-2682. PMID: 37017737, PMCID: PMC10330155, DOI: 10.1007/s00259-023-06209-0.
- Van Dyck C, O'Dell R, Mecca A. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12388. PMID: 37187779, PMCID: PMC10175943, DOI: 10.1002/trc2.12388.
- Lanctôt K, Sankhe K, Perin J, Herrmann N, Brawman-Mintzer O, Lerner A, Mintzer J, Padala P, Rosenberg P, Shade D, van Dyck C, Porsteinsson A. Correlation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial. American Journal Of Geriatric Psychiatry 2023, 31: s100-s101. DOI: 10.1016/j.jagp.2022.12.146.
- Mah E, Lanctôt K, Chen Q, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Mintzer J, Herrmann N. Cost Consequence Analysis of ADMET 2. American Journal Of Geriatric Psychiatry 2023, 31: s101. DOI: 10.1016/j.jagp.2022.12.147.
- Sabbagh M, van Dyck C. Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke. New England Journal Of Medicine 2023, 388: 480-480. PMID: 36599073, DOI: 10.1056/nejmc2215907.
- Mallinckrodt C, Tian Y, Aisen P, Barkhof F, Cohen S, Dent G, Hansson O, Harrison K, Iwatsubo T, Mummery C, Muralidharan K, Nestorov I, Nisenbaum L, Rajagovindan R, von Hehn C, van Dyck C, Vellas B, Wu S, Zhu Y, Sandrock A, Chen T, Budd Haeberlein S. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab. The Journal Of Prevention Of Alzheimer's Disease 2023, 10: 171-177. PMID: 36946443, DOI: 10.14283/jpad.2023.6.
- Cohen S, van Dyck C, Gee M, Doherty T, Kanekiyo M, Dhadda S, Li D, Hersch S, Irizarry M, Kramer L. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer’s Disease. The Journal Of Prevention Of Alzheimer's Disease 2023, 10: 771-777. PMID: 37874099, DOI: 10.14283/jpad.2023.123.
- O'Dell R, Mecca A, Waszak J, Sharp E, Chen M, Naganawa M, Toyonaga T, Lu Y, Chupak A, Cooper E, Lam J, Miller A, Waldner E, Weibley H, Zhao Y, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Association of synaptic density and glucose metabolism with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB‐J and [18F]FDG. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.062595.
- Salardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065162.
- Salardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer’s Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065064.
- Gordon B, Flores S, Dincer A, Keefe S, McKay N, Hobbs D, Wisch J, Hornbeck R, Franklin E, Jack C, Koeppe R, Xiong C, McDade E, van Dyck C, Klein G, Pariente J, Bateman R, Morris J, Perrin R, Benzinger T. Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063285.
- Pandey K, Waybright L, Duong D, Malagise E, Blennow K, Zetterberg H, Mecca A, van Dyck C, Caggiano A, Seyfried N, Hamby M. CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer’s disease patients from the SPARC clinical trial. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.068166.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. Nanoscale imaging of pT217‐tau in aged rhesus macaque: Trans‐synaptic propagation and seeding of tau pathology in entorhinal cortex. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.064956.
- Lanctôt K, Perin J, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.066932.
- Gordon B, Flores S, Dincer A, Keefe S, McKay N, Hobbs D, Wisch J, Hornbeck R, Franklin E, Jack C, Koeppe R, Xiong C, van Dyck C, McDade E, Klein G, Pariente J, Bateman R, Morris J, Ances B, Benzinger T, Perrin R. Examining the effects of sex and age on tau PET binding in the absence of beta‐amyloid pathology. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.061090.
- Villa L, Colic L, Kim J, Sankar A, Goldman D, Lessing B, Pittman B, Alexopoulos G, van Dyck C, Blumberg H. Aging of the brain in bipolar disorder: Illness- and onset-related effects in cortical thickness and subcortical gray matter volume. Journal Of Affective Disorders 2022, 323: 875-883. PMID: 36526112, PMCID: PMC9839524, DOI: 10.1016/j.jad.2022.12.026.
- van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer L, Iwatsubo T. Lecanemab in Early Alzheimer’s Disease. New England Journal Of Medicine 2022, 388: 9-21. PMID: 36449413, DOI: 10.1056/nejmoa2212948.
- Wilson E, Young C, Ramos Benitez J, Swarovski M, Feinstein I, Vandijck M, Le Guen Y, Kasireddy N, Shahid M, Corso N, Wang Q, Kennedy G, Trelle A, Lind B, Channappa D, Belnap M, Ramirez V, Skylar-Scott I, Younes K, Yutsis M, Le Bastard N, Quinn J, van Dyck C, Nairn A, Fredericks C, Tian L, Kerchner G, Montine T, Sha S, Davidzon G, Henderson V, Longo F, Greicius M, Wagner A, Wyss-Coray T, Poston K, Mormino E, Andreasson K. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease. Alzheimer's Research & Therapy 2022, 14: 172. PMID: 36371232, PMCID: PMC9652927, DOI: 10.1186/s13195-022-01116-2.
- Kelly K, O'Dell R, Toyonaga T, Barcelos N, Gelernter J, Varma P, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. P95. Cortical Amyloid Burden is Associated With Basal Forebrain but Not Medial Temporal Lobe Atrophy in Adults at Varying APOE ɛ4 Risk for Alzheimer’s Disease. Biological Psychiatry 2022, 91: s125-s126. DOI: 10.1016/j.biopsych.2022.02.329.
- Kelly K, Toyonaga T, Zhao W, Barcelos N, Gelernter J, Varma P, Nabulsi N, Wyk B, Huang Y, Carson R, van Dyck C, Mecca A. The relationship between cortical amyloid burden and basal forebrain volume in adults at varying APOE ?4 risk for Alzheimer's disease. American Journal Of Geriatric Psychiatry 2022, 30: s25. DOI: 10.1016/j.jagp.2022.01.301.
- Silva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PET. American Journal Of Geriatric Psychiatry 2022, 30: s26. DOI: 10.1016/j.jagp.2022.01.303.
- O'Dell R, van Dyck C, Mecca A. All that's Amnestic Isn't Alzheimer's: a Clinical Case Report of an Alzheimer's disease-like Amnestic Syndrome with Incongruent Biomarkers. American Journal Of Geriatric Psychiatry 2022, 30: s24. DOI: 10.1016/j.jagp.2022.01.295.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. Subcellular localization of PDE4D and HCN1 in rhesus macaque entorhinal cortex layer II: Signature of vulnerability in Alzheimer’s disease. Alzheimer's & Dementia 2022, 17 DOI: 10.1002/alz.054671.
- Budd Haeberlein S, Aisen P, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery C, Muralidharan K, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck C, Vellas B, Wu S, Zhu Y, Sandrock A. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. The Journal Of Prevention Of Alzheimer's Disease 2022, 9: 197-210. PMID: 35542991, DOI: 10.14283/jpad.2022.30.
- Chaudhary S, Zhornitsky S, Chao H, van Dyck C, Li C. Hypothalamic Functional Connectivity and Apathy in People with Alzheimer's Disease and Cognitively Normal Healthy Controls. Journal Of Alzheimer's Disease 2022, 90: 1615-1628. PMID: 36314209, PMCID: PMC10064487, DOI: 10.3233/jad-220708.
- Mecca A, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Zhao W, Nabulsi N, Brinkmalm A, Kvartsberg H, Schöll M, Arnsten A, Huang Y, Blennow K, Zetterberg H, Carson R, van Dyck C, Nilsson J. Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: Biomarkers of synaptic density in Alzheimer’s disease. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054831.
- Mintzer J, Scherer R, Drye L, Lanctôt K, Rosenberg P, Herrmann N, Padala P, Brawman‐Mintzer O, Lerner A, Levey A, Porsteinsson A, van Dyck C. Apathy in Dementia Methylphenidate Trial 2 (ADMET2): Results of a phase III, placebo‐controlled, double‐blind, 6‐month, multi‐center, randomized clinical trial. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.051489.
- Chen C, McCullough A, Gordon B, Joseph‐Mathurin N, Wang G, Li Y, Xiong C, Pontecorvo M, Klein G, Shcherbinin S, Higgins I, Masters C, Clifford D, van Dyck C, Masellis M, Hsiung G, Gauthier S, Bateman R, McDade E, Salloway S, Benzinger T. [11C]PiB and [18F]AV45 PET radiotracers show different rates of amyloid‐β clearance. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.056094.
- Baker L, Cotman C, Morrison R, Katula J, Chmelo E, Hodge H, Johnson C, Kipperman S, Matthews G, Bennett D, Mason J, LaCroix A, van Dyck C, Okonkwo O, Tam S, Fairchild J, Li C, Welsh‐Bohmer K, Feldman H, Group T. EXERT: Impact of COVID‐19 on retention and intervention delivery of a large multisite exercise trial in adults with MCI. Alzheimer's & Dementia 2021, 17: e056518. PMCID: PMC9011773, DOI: 10.1002/alz.056518.
- van Dyck C, Sharp E, O'Dell R, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A. Synaptic density is associated with cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐J. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054213.
- Zhou B, Wang R, Chen M, Mecca A, O’Dell R, Van Dyck C, Carson R, Duncan J, Liu C. Synthesizing Multi-tracer PET Images for Alzheimer’s Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial Network. 2021, 12906: 34-43. DOI: 10.1007/978-3-030-87231-1_4.
- O'Dell R, Mecca A, Sharp E, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Carson R, Arnsten A, van Dyck C. Synaptic Loss is Associated With Cognitive Impairment in Early Alzheimer’s Disease: A PET Imaging Study With [11C]UCB-J. Biological Psychiatry 2021, 89: s107-s108. DOI: 10.1016/j.biopsych.2021.02.276.
- Pathak GA, Wendt FR, Levey DF, Mecca AP, van Dyck CH, Gelernter J, Polimanti R. Pleiotropic effects of telomere length loci with brain morphology and brain tissue expression. Human Molecular Genetics 2021, 30: 1360-1370. PMID: 33831179, PMCID: PMC8255129, DOI: 10.1093/hmg/ddab102.
- Villa L, Colic L, Sankar A, Goldman D, Lessing B, Alexopoulos G, van Dyck C, Blumberg H. Age-Related Brain Structure Differences, by Age of Onset, in Older Adults with Bipolar Disorder. American Journal Of Geriatric Psychiatry 2021, 29: s26. DOI: 10.1016/j.jagp.2021.01.019.
- O'Dell R, Mecca A, Chen M, Naganawa M, Toyonaga T, Lu Y, Godek T, Harris J, Bartlett H, Banks E, Kominek V, Zhao W, Nabulsi N, Ropchan J, Ye Y, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C. Association of Aß deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. American Journal Of Geriatric Psychiatry 2021, 29: s37-s40. DOI: 10.1016/j.jagp.2021.01.034.
- Sharp E, O'Dell R, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A, van Dyck C. Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. American Journal Of Geriatric Psychiatry 2021, 29: s119-s120. DOI: 10.1016/j.jagp.2021.01.114.
- Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's diseaseO'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Banks E, Bartlett H, Harris J, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease. American Journal Of Geriatric Psychiatry 2021, 29: s47-s48. DOI: 10.1016/j.jagp.2021.01.041.
- Salardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Laltoo E, Savoia S, O'Dell R, Harris J, Godek T, Nabulsi N, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037792.
- Mecca A, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Harris J, Bartlett H, Banks E, Kominek V, Nabulsi N, Najafzadeh S, Wyk B, Brinkmalm A, Kvartsberg H, Schöll M, Arnsten A, Huang Y, Blennow K, Zetterberg H, Carson R, van Dyck C. Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.044211.
- Salardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Laltoo E, Savoia S, O'Dell R, Harris J, Godek T, Nabulsi N, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. 11C‐PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043584.
- O'Dell R, Mecca A, Chen M, Godek T, Harris J, Bartlett H, Banks E, Kominek V, Zhao W, Naganawa M, Toyonaga T, Lu Y, Nabulsi N, Ropchan J, Ye Y, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. Association between cerebral amyloid accumulation and synaptic density in Alzheimer’s disease: A multitracer PET study. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043631.
- Fang X, Mecca A, Naganawa M, O'Dell R, Chen M, van Dyck C, Carson R. ICA‐derived sources of synaptic density PET ([11C]UCB‐J) relate to cognitive impairment severity in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.041197.
- Mecca A, O'Dell R, Chen M, Naganawa M, Toyonaga T, Godek T, Harris J, Bartlett H, Zhao W, Gallezot J, Nabulsi N, Ropchan J, Ye Y, Wyk B, Arnsten A, Huang Y, Carson R, van Dyck C. In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037791.
- O'Dell R, Naganawa M, Toyonaga T, Young J, Dahal R, Singh E, Waheed A, Banks E, Harris J, Chen M, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Validation of a simplified tissue‐to‐reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer’s disease using [11C]UCB‐J PET. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.045928.
- LaCroix A, van Dyck C, Okonkwo O, Tam S, Fairchild J, Li C, Welsh‐Bohmer K, Shadyab A, Matthews G, Bennett D, Shadyab A, Schafer K, Morrison R, Kipperman S, Tan D, Feldman H, Cotman C, Baker L, Group E. Recruitment for a multi‐site randomized controlled trial of aerobic exercise for older adults with amnestic mild cognitive impairment: The EXERT trial. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.044658.
- Salloway S, Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Farlow M, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, van Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Baudler M, Delmar P, Doody R, Fontoura P, Kerchner G, Team D. Gantenerumab in‐depth outcomes. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.038049.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. The calcium‐containing smooth endoplasmic reticulum is a focus of risk factors for early‐ and late‐onset Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.047651.
- Farlow M, Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Salloway S, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, van Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Andersen S, Holdridge K, Mintun M, Sims J, Yaari R, Team D. Solanezumab in‐depth outcomes. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.038028.
- Leslie S, Datta D, Wang M, van Dyck C, Arnsten A, Nairn A. Biochemical characterization of age‐related calcium‐cAMP‐PKA signaling dysregulation and its effect on tau pathology in rhesus monkey cortex. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.042017.
- van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanctôt KL, Rosenberg PB. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. American Journal Of Geriatric Psychiatry 2020, 29: 51-62. PMID: 32461027, PMCID: PMC7641967, DOI: 10.1016/j.jagp.2020.04.026.
- O'Dell R, Mecca A, Chen M, Godek T, Harris J, Bartlett H, Zhao W, Naganawa M, Toyonaga T, Lu Y, Nabulsi N, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDY. American Journal Of Geriatric Psychiatry 2020, 28: s123-s124. DOI: 10.1016/j.jagp.2020.01.153.
- Mecca AP, McDonald JW, Michalak HR, Godek TA, Harris JE, Pugh EA, Kemp EC, Chen MK, Salardini A, Nabulsi NB, Lim K, Huang Y, Carson RE, Strittmatter SM, van Dyck CH. PET imaging of mGluR5 in Alzheimer’s disease. Alzheimer's Research & Therapy 2020, 12: 15. PMID: 31954399, PMCID: PMC6969979, DOI: 10.1186/s13195-020-0582-0.
- van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. JAMA Neurology 2019, 76: 1219-1229. PMID: 31329216, PMCID: PMC6646979, DOI: 10.1001/jamaneurol.2019.2050.
- Datta D, Morozov Y, van Dyck C, Arnsten A. F164. Ultrastructural Localization of Classical Complement Cascade Signaling Protein C1q in Rhesus Macaque Dorsolateral Prefrontal Cortex. Biological Psychiatry 2019, 85: s276-s277. DOI: 10.1016/j.biopsych.2019.03.701.
- Gupta M, O'Dell R, Gelernter J, Carson R, van Dyck C, Mecca A. ASSOCIATION BETWEEN ODOR IDENTIFICATION AND REGIONAL GRAY MATTER IN EARLY PRECLINICAL ALZHEIMER'S DISEASE. American Journal Of Geriatric Psychiatry 2019, 27: s143-s144. DOI: 10.1016/j.jagp.2019.01.098.
- O'Dell R, Gupta M, Gelernter J, Carson R, van Dyck C, Mecca A. REGION-SPECIFIC ATROPHY AS MEASURED BY CORTICAL GRAY MATTER VOLUME IS ASSOCIATED WITH BOTH REGIONAL AND TOTAL CORTICAL AMYLOID-BETA BURDEN IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE. American Journal Of Geriatric Psychiatry 2019, 27: s145-s146. DOI: 10.1016/j.jagp.2019.01.100.
- Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurology 2018, 75: 1215-1224. PMID: 30014145, PMCID: PMC6233853, DOI: 10.1001/jamaneurol.2018.1836.
- Barcelos NM, Van Ness PH, Wagner AF, MacAvoy MG, Mecca AP, Anderson GM, Trentalange M, Hawkins KA, Sano M, Arnsten AFT, van Dyck CH. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. Neurobiology Of Aging 2018, 70: 117-124. PMID: 30007160, PMCID: PMC6503670, DOI: 10.1016/j.neurobiolaging.2018.05.033.
- Mecca A, Chen M, Naganawa M, Finnema S, Toyonaga T, Lin S, McDonald J, Michalak H, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Poster Number: NR 14 Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials? American Journal Of Geriatric Psychiatry 2018, 26: s145-s146. DOI: 10.1016/j.jagp.2018.01.176.
- van Dyck CH. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise. Biological Psychiatry 2017, 83: 311-319. PMID: 28967385, PMCID: PMC5767539, DOI: 10.1016/j.biopsych.2017.08.010.
- Lanctot K, Scherer R, Li A, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J. [O1–01–06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS. Alzheimer's & Dementia 2017, 13: p184-p184. DOI: 10.1016/j.jalz.2017.07.038.
- Mecca A, Rogers K, Jacobs Z, McDonald J, Michalak H, DellaGioia N, Nabulsi N, Matuskey D, Esterlis I, Carson R, van Dyck C. Poster Number: EI 39 Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18F]FPEB and PET. American Journal Of Geriatric Psychiatry 2017, 25: s96-s97. DOI: 10.1016/j.jagp.2017.01.110.
- van Dyck C, Mecca A, Wang S, Barcelos N, Planeta-Wilson B, Gelernter J, Van Ness P, Carson R. P3‐143: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first‐degree relatives at varying ApoE4 risk for Alzheimer's disease. Alzheimer's & Dementia 2015, 11: p680-p681. DOI: 10.1016/j.jalz.2015.06.1011.
- van Dyck C, Mecca A, Wang S, Barcelos N, Planeta-Wilson B, Gelernter J, Van Ness P, Carson R. IC‐P‐101: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first‐degree relatives at varying ApoE4 risk for Alzheimer's disease. Alzheimer's & Dementia 2015, 11: p69-p69. DOI: 10.1016/j.jalz.2015.06.123.
- Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC, Rosenberg BJ, Sekine-Konno T, Varma P, Chen K, Koleske AJ, Reiman EM, Strittmatter SM, van Dyck CH. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimer's Research & Therapy 2015, 7: 35. PMID: 25874001, PMCID: PMC4396171, DOI: 10.1186/s13195-015-0119-0.
- Istace A, Bracoud L, Berman R, Luo F, Roche F, Salloway S, van Dyck C, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Ferris S, Grill J, Gouttard S, Schaerer J, Hayes W, Kaplita S, Belaroussi B, Yu H, Cedarbaum J, Feldman H, Pachai C, Coric V. IC‐P‐108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. Alzheimer's & Dementia 2014, 10: p60-p61. DOI: 10.1016/j.jalz.2014.05.114.
- Coric V, Salloway S, van Dyck C, Kerselaers W, Kaplita S, Curtis C, Ross J, Richter R, Andreasen N, Brody M, Sharma S, Cedarbaum J, Berman R. P1–343: A phase II study of the gamma‐secretase inhibitor avagacestat (BMS‐708163) in predementia Alzheimer's disease. Alzheimer's & Dementia 2013, 9: p283-p283. DOI: 10.1016/j.jalz.2013.05.569.
- van Dyck C, Barcelos N, Brück A, Planeta‐Wilson B, Gelernter J, Carson R. IC‐O1‐03: Amyloid burden and neuropsychological performance in presymptomatic first‐degree relatives at varying APOE‐ɛ4 risk for Alzheimer's disease. Alzheimer's & Dementia 2012, 8: p5-p5. DOI: 10.1016/j.jalz.2012.05.018.
- Bracoud L, Coric V, van Dyck C, Andreasen N, Ross J, Brody M, Curtis C, Belaroussi B, Yu H, Kaplita S, Feldman H, Pachai C, Berman R. IC‐P‐140: Baseline clinical scores and volumetric MRI parameters across subjects randomized in mild‐to‐moderate (BMS CN156‐013) and predementia (BMS CN156‐018) Alzheimer's disease clinical trials of avagacestat. Alzheimer's & Dementia 2012, 8: p73-p74. DOI: 10.1016/j.jalz.2012.05.174.
- Bracoud L, Coric V, van Dyck C, Andreasen N, Ross J, Brody M, Curtis C, Belaroussi B, Yu H, Kaplita S, Feldman H, Pachai C, Berman R. P2‐414: Baseline clinical scores and volumetric MRI parameters across subjects randomized in mild‐to‐moderate (BMS CN156‐013) and predementia (BMS CN156‐018) Alzheimer's disease clinical trials of avagacestat. Alzheimer's & Dementia 2012, 8: p409-p409. DOI: 10.1016/j.jalz.2012.05.2039.
- Farlow M, Arnold SE, van Dyck C, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's & Dementia 2012, 8: 261-271. PMID: 22672770, DOI: 10.1016/j.jalz.2011.09.224.
- van Dyck C, Brück A, Barcelos N, Planeta‐Wilson B, Benincasa A, MacAvoy M, Ding Y, Gelernter J, Carson R. IC‐P‐106: Amyloid‐ß burden and neuropsychological test performance in cognitively normal first‐degree relatives at varying genetic risk for Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s51-s52. DOI: 10.1016/j.jalz.2011.05.071.
- van Dyck C, Brück A, Barcelos N, Planeta‐Wilson B, Benincasa A, MacAvoy M, Ding Y, Gelernter J, Carson R. P1‐387: Amyloid‐ß burden and neuropsychological test performance in cognitively normal first‐degree relatives at varying genetic risk for Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s236-s236. DOI: 10.1016/j.jalz.2011.05.668.
- Salloway S, Porsteinsson A, Sperling R, Keren R, van Dyck C, Tariot P, Gilman S, Crans G, Hernandez R, Quinn G, Bairu M, Cedarbaum J, Pastrak A, Abushakra S. P2‐499: Safety and efficacy results of a phase II randomized, placebo‐controlled, dose‐ranging study of elnd005 (scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s472-s472. DOI: 10.1016/j.jalz.2011.05.1371.
- Salloway S, Coric V, Brody M, Andreasen N, van Dyck C, Soininen H, Thein S, Shiovitz T, Kumar S, Pilcher G, Colby S, Rollin L, Feldman H, Berman R. O4‐06‐08: Safety and tolerability of BMS‐708163 in a phase II study in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s695-s696. DOI: 10.1016/j.jalz.2011.05.2011.
- Porsteinsson A, Sperling R, Salloway S, Keren R, van Dyck C, Tariot P, Arnold D, Crans G, Hernandez R, Liang E, Bairu M, Cedarbaum J, Pastrak A, Abushakra S. O4‐06‐07: Imaging and cerebrospinal fluid biomarker results of a phase II dose‐ranging study of ELND005 (Scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s695-s695. DOI: 10.1016/j.jalz.2011.05.2010.
- Ding Y, Planeta-Wilson B, Hannestad J, Gallezot J, Lin S, Williams W, Quinlan D, Carson R, van Dyck C. The role of norepinephrine transporter in attention deficit hyperactivity disorder. NeuroImage 2010, 52: s108. DOI: 10.1016/j.neuroimage.2010.04.087.
- Mitsis EM, Reech KM, Bois F, Tamagnan GD, MacAvoy MG, Seibyl JP, Staley JK, van Dyck CH. 123I-5-IA-85380 SPECT Imaging of Nicotinic Receptors in Alzheimer Disease and Mild Cognitive Impairment. Journal Of Nuclear Medicine 2009, 50: 1455-1463. PMID: 19690024, DOI: 10.2967/jnumed.109.064030.
- Santhosh L, Estok KM, Vogel RS, Tamagnan GD, Baldwin RM, Mitsis EM, MacAvoy MG, Staley JK, van Dyck CH. Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET. Psychiatry Research 2009, 173: 212-217. PMID: 19682865, DOI: 10.1016/j.pscychresns.2009.03.007.
- Harrington C, Sawchak S, Chiang C, Davies J, Saunders A, Irizarry M, Zvartau‐Hind M, van Dyck C, Gold M. P4‐299: Effects Of Rosiglitazone‐extended Release As Adjunctive Therapy To Acetylcholinesterase Inhibitors Over 48 Weeks On Cognition In Apoe4‐stratified Subjects With Mild‐to‐moderate Alzheimer's Disease. Alzheimer's & Dementia 2009, 5: e17-e18. DOI: 10.1016/j.jalz.2009.07.079.
- Mitsis EM, Cosgrove KP, Staley JK, Bois F, Frohlich EB, Tamagnan GD, Estok KM, Seibyl JP, van Dyck CH. Age-related decline in nicotinic receptor availability with [123I]5-IA-85380 SPECT. Neurobiology Of Aging 2008, 30: 1490-1497. PMID: 18242781, PMCID: PMC3523217, DOI: 10.1016/j.neurobiolaging.2007.12.008.
- Batis J, Esterlis I, Bois F, Cosgrove K, Stiklus S, Kloczynski T, McKee S, Jatlow P, O'Malley S, Seibyl J, Tamagnan G, Van Dyck C, Staley J. SPECT imaging of [123I]5-IA-85380 binding to beta2-nicotinic acetylcholine receptors in healthy smokers: Assessment of nondisplaceable uptake. NeuroImage 2008, 41: t175. DOI: 10.1016/j.neuroimage.2008.04.142.
- Batis J, Yang B, Cosgrove K, Bois F, Esterlis I, Stiklus S, Kloczynski T, Perry E, Seibyl J, Tamagnan G, Van Dyck C, Gelernter J, Staley J. Single nucleotide polymorphisms of ANKK1 and CHRNA4: Influence on nicotinic acetylcholine receptor availability in nonsmokers measured using [123I]5-IA-85380 SPECT. NeuroImage 2008, 41: t174. DOI: 10.1016/j.neuroimage.2008.04.141.
- van Dyck CH, Avery RA, MacAvoy MG, Marek KL, Quinlan DM, Baldwin RM, Seibyl JP, Innis RB, Arnsten AF. Striatal dopamine transporters correlate with simple reaction time in elderly subjects. Neurobiology Of Aging 2007, 29: 1237-1246. PMID: 17363113, PMCID: PMC3523216, DOI: 10.1016/j.neurobiolaging.2007.02.012.
- Zdanys KF, Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, Garman KS, Tampi RR, Gelernter J, van Dyck CH. Apolipoprotein E ɛ4 Allele Increases Risk for Psychotic Symptoms in Alzheimer's Disease. Neuropsychopharmacology 2006, 32: 171-179. PMID: 16841077, DOI: 10.1038/sj.npp.1301148.
- Staley J, Tellioglu T, Bois F, Palazzo C, McGuire-Schwartz N, Cosgrove K, van Dyck C, Tamagnan G, Seibyl J, Krystal J, D'Souza D. [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers. NeuroImage 2006, 31: t154. DOI: 10.1016/j.neuroimage.2006.04.137.
- Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiology Of Aging 2005, 27: 1416-1424. PMID: 16182410, DOI: 10.1016/j.neurobiolaging.2005.08.002.
- Petersen R, Thomas R, Grundman M, Bennett D, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck C, Thal L. [O1‐04‐04]: Operational criteria for patient recruitment in trials of mild cognitive impairment. Alzheimer's & Dementia 2005, 1: s87-s87. DOI: 10.1016/j.jalz.2005.06.303.
- KUGAYA A, EPPERSON C, van DYCK C, FUJITA M, INNIS R. Dr. Kugaya and Colleagues Reply. American Journal Of Psychiatry 2004, 161: 2136-a-2136. DOI: 10.1176/appi.ajp.161.11.2136-a.
- van Dyck C, Cummings J, Schmitt F, Graham S, Olin J, Jin J, Tariot P. P4.028 Functional and behavioral effects of memantinein Alzheimer's disease. European Neuropsychopharmacology 2004, 14: s334-s335. DOI: 10.1016/s0924-977x(04)80452-8.
- Cummings J, van Dyck C, Schmitt F, Graham S, Olin J, Jin J, Tariot P. P1-315 Functional and behavioral effects of memantine in Alzheimer's disease. Neurobiology Of Aging 2004, 25: s186. DOI: 10.1016/s0197-4580(04)80628-6.
- Karlawish J, James B, Kim S, Knopman D, van Dyck C, Marson D. P2-393 Alzheimer's disease patient and caregiver attitudes about proxy informed consent. Neurobiology Of Aging 2004, 25: s345. DOI: 10.1016/s0197-4580(04)81135-7.
- Martinez D, Gelernter J, Abi-Dargham A, van Dyck C, Kegeles L, Innis R, Laruelle M. The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans. Neuropsychopharmacology 2001, 24: 553-560. PMID: 11282255, DOI: 10.1016/s0893-133x(00)00216-5.
- Staley J, Van Dyck C, Tan P, Tikriti M, Ramsby Q, Klump H, Ng C, Garg P, Soufer R, Baldwin R, Innis R. Comparison of [18F]altanserin and [18F]deuteroaltanserin for PET imaging of serotonin2A receptors in baboon brain: pharmacological studies. Nuclear Medicine And Biology 2001, 28: 271-279. PMID: 11323237, DOI: 10.1016/s0969-8051(00)00212-2.
- Soares J, van Dyck C, Tan P, Zoghbi S, Garg P, Soufer R, Baldwin R, Fujita M, Staley J, Fu X, Amici L, Seibyl J, Innis R. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin. Psychiatry Research 2001, 106: 81-93. PMID: 11306248, DOI: 10.1016/s0925-4927(01)00071-3.
- van Dyck C. Neuroimaging in alzheimer’s disease: Relevance for treatment. Current Psychiatry Reports 2001, 3: 13-19. PMID: 11177754, DOI: 10.1007/s11920-001-0066-2.
- van Dyck C, Soares J, Tan P, Staley J, Baldwin R, Amici L, Fu X, Garg P, Seibyl J, Charney D, Innis R. Equilibrium modeling of 5-ht2a receptors with [18f]deuteroaltanserin and pet: feasibility of a constant infusion paradigm. Nuclear Medicine And Biology 2000, 27: 715-722. PMID: 11150702, DOI: 10.1016/s0969-8051(00)00160-8.
- Avery R, Franowicz J, Studholme C, van Dyck C, Arnsten A. The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Cortex of Monkeys Performing a Spatial Working Memory Task. Neuropsychopharmacology 2000, 23: 240-249. PMID: 10942848, DOI: 10.1016/s0893-133x(00)00111-1.
- Mulnard R, Cotman C, Kawas C, van Dyck C, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Study L. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial. Obstetrical & Gynecological Survey 2000, 55: 439-440. DOI: 10.1097/00006254-200007000-00021.
- van Dyck C, Malison R, Seibyl J, Laruelle M, Klumpp H, Zoghbi S, Baldwin R, Innis R. Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT. Neurobiology Of Aging 2000, 21: 497-501. PMID: 10924762, DOI: 10.1016/s0197-4580(00)00152-4.
- van Dyck C, Basso M, Yang J, Half L, MacAvoy M, Varma P, Gelernter J. Apolipoprotein E ε4 allele is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiology Of Aging 2000, 21: 39. DOI: 10.1016/s0197-4580(00)82852-3.
- Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D’Souza D, Krystal J, Seibyl J, Baldwin R, Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT. Biological Psychiatry 2000, 47: 371-379. PMID: 10704949, DOI: 10.1016/s0006-3223(99)00257-7.
- Mulnard R, Cotman C, Kawas C, van Dyck C, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal L, Study F. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial. JAMA 2000, 283: 1007-1015. PMID: 10697060, DOI: 10.1001/jama.283.8.1007.
- van Dyck CH, Newhouse P, Falk WE, Mattes JA. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. Archives Of General Psychiatry 2000, 57: 157-64. PMID: 10665618, DOI: 10.1001/archpsyc.57.2.157.
- Verhoeff N, Soares J, D’Souza C, Gil R, Degen K, Abi-Dargham A, Zoghbi S, Fujita M, Rajeevan N, Seibyl J, Krystal J, van Dyck C, Charney D, Innis R. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Research 1999, 91: 163-173. PMID: 10641580, DOI: 10.1016/s0925-4927(99)00027-x.
- Malison R, Price L, Berman R, van Dyck C, Pelton G, Carpenter L, Sanacora G, Owens M, Nemeroff C, Rajeevan N, Baldwin R, Seibyl J, Innis R, Charney D. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry 1998, 44: 1090-1098. PMID: 9836013, DOI: 10.1016/s0006-3223(98)00272-8.
- Gelernter J, Van Dyck C, van Kammen D, Malison R, Price L, Cubells J, Berman R, Charney D, Heninger G. Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. American Journal Of Medical Genetics 1997, 74: 497-500. PMID: 9342199, DOI: 10.1002/(sici)1096-8628(19970919)74:5<497::aid-ajmg8>3.0.co;2-l.
- van Dyck C, Lin C, Robinson R, Cellar J, Smith E, Nelson J, Arnsten A, Hoffer P. The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer’s disease. Psychopharmacology 1997, 132: 217-226. PMID: 9292621, DOI: 10.1007/s002130050339.
- Arnsten A, Lin C, Van Dyck C, Stanhope K. The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiology Of Aging 1997, 18: 21-28. PMID: 8983029, DOI: 10.1016/s0197-4580(96)00162-5.
- Laruelle M, Abi-Dargham A, van Dyck C, Krystal J, Charney D, Innis R. 208. Increased striatal dopamine release in drug free schizophrenic subjects. Biological Psychiatry 1996, 39: 560. DOI: 10.1016/0006-3223(96)84153-9.
- Laruelle M, Abi-Dargham A, Gil R, van Dyck C, Erdos J, D'Souza D, Rosenblatt W, McCance-Katz E, Zea-Ponce Y, Zoghbi S, Baldwin R, Hoffer P, Krystal J, Charney D, Innis R. SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia. Schizophrenia Research 1996, 18: 198-199. DOI: 10.1016/0920-9964(96)85619-2.
- van Dyck C, Seibyl J, Stubbs J, Zoghbi S, Wisniewski G, Baldwin R, Zea-Ponce Y, Charney D, Hoffer P, Innis R. Human biodistribution and dosimetry of the SPECT D2 dopamine receptor radioligand [123I]IBF. Nuclear Medicine And Biology 1996, 23: 9-16. PMID: 9004921, DOI: 10.1016/0969-8051(95)02003-9.
- van Dyck C, Rosen M, Thomas H, McMahon T, Wallace E, O'Connor P, Sullivan M, Krystal J, Hoffer P, Woods S, Kosten T. SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry Research 1994, 55: 181-191. PMID: 7701033, DOI: 10.1016/0925-4927(94)90013-2.
- Laruelle M, Al-Tikriti M, Van Dyck C, Zoghbi S, Zea-Ponce Y, Baldwin R, Charney D, Hoffer P, Innis R. D-amphetamine displacement of [123I]IBF equilibrium binding in primates: A new paradigm to investigate D-amphetamine induced dopamine release. Schizophrenia Research 1993, 9: 201. DOI: 10.1016/0920-9964(93)90423-g.
- Rosen M, Bridge T, O'Malley S, Pearsall H, Martini B, O'Connor P, Brett‐Smith H, Thomas H, Van Dyck C, Woods S, Kosten T. Peptide T Treatment of Cognitive Impairment in HIV‐Positive Intravenous Drug Users. American Journal On Addictions 1992, 1: 332-338. DOI: 10.1111/j.1521-0391.1992.tb00359.x.
- Rosen M, Bridge T, O'Malley S, Pearsall H, Martini B, O'Connor P, Brett-Smith H, Thomas H, van Dyck C, Woods S, Kosten T. Peptide T Treatment of Cognitive Impairment in HIV-Positive Intravenous Drug Users. American Journal On Addictions 1992, 1: 332-338. DOI: 10.3109/10550499208993153.
Departments and Programs
Locations
1
1 of 2
- Yale Alzheimer's Disease Research Unit1 Church StreetSte 8th FloorNew Haven, CT 06510
- Adler Geriatric Assessment Center874 Howard AvenueNew Haven, CT 06519
Titles
- Professor of Psychiatry, Neurology, and Neuroscience
- Director, Alzheimer's Disease Research Unit
- Director, Yale Alzheimer's Disease Research Center
- Director, Division of Aging and Geriatric Psychiatry
Education & Training
- MDNorthwestern University (1984)
- BAYale University (1978)
- ResidentYale-New Haven Hospital
- FellowYale University School of Medicine
Languages Spoken
- English
- Français (French)
Additional Information
Honors & Recognitions
- “Leader in Advancing Research” Award: Alzheimer’s Association (2017)
- Best Doctors in New York (Top 2%), as Featured in New York Magazine: Castle Connolly (2005), (2014)
- “Compassion and Cure” Award: Alzheimer’s Association (2005)
- Junior Investigator Award: American Association for Geriatric Psychiatry (1996)
Board Certifications
- AB of Psychiatry & Neurology, Psychiatry (1991)
Publications
- Datta D, Perone I, Wijegunawardana D, Liang F, Morozov Y, Arellano J, Duque A, Xie Z, van Dyck C, Joyce M, Arnsten A. Nanoscale imaging of pT217‐tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early‐stage neurodegeneration. Alzheimer's & Dementia 2024 PMID: 38445818, DOI: 10.1002/alz.13737.
- Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.
- Wang G, Li Y, Xiong C, Benzinger T, Gordon B, Hassenstab J, Aschenbrenner A, McDade E, Clifford D, Libre‐Guerra J, Shi X, Mummery C, van Dyck C, Lah J, Honig L, Day G, Ringman J, Brooks W, Fox N, Suzuki K, Levin J, Jucker M, Delmar P, Bittner T, Bateman R, Team F. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease. Alzheimer's & Dementia 2024 PMID: 38400532, DOI: 10.1002/alz.13735.
- van Dyck C, Mecca A, O’Dell R, Bartlett H, Diepenbrock N, Huang Y, Hamby M, Grundman M, Catalano S, Caggiano A, Carson R. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease. Alzheimer's Research & Therapy 2024, 16: 20. PMID: 38273408, PMCID: PMC10809445, DOI: 10.1186/s13195-024-01382-2.
- Trainer A, Xu W, Chase A, O'Dell R, Tun S, Li J, Ju S, van Dyck C, Mecca A, Fredricks C. Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079435.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. Anatomical characterization of pT217‐tau in aged rhesus macaque association cortices: Relevance for trans‐synaptic propagation in sporadic Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.075998.
- Tumati S, Vieira D, Bawa K, Andreazza A, Mintzer J, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Herrmann N, Lanctôt K. Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079161.
- Young J, Park H, Kim M, Par-Young J, Bartlett H, Kim H, Unlu S, Osmani L, Shin M, Bucala R, van Dyck C, Allore H, Mecca A, You S, Kang I. Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease. Immunity & Ageing 2023, 20: 71. PMID: 38042785, PMCID: PMC10693128, DOI: 10.1186/s12979-023-00396-y.
- Toyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot J, Matuskey D, Mecca A, Pittman B, Dias M, Nabulsi N, Finnema S, Chen M, Arnsten A, Radhakrishnan R, Skosnik P, D’Souza D, Esterlis I, Huang Y, van Dyck C, Carson R. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 51: 1012-1022. PMID: 37955791, DOI: 10.1007/s00259-023-06487-8.
- Bathla S, Datta D, Liang F, Barthelemy N, Wiseman R, Slusher B, Asher J, Zeiss C, Ekanayake‐Alper D, Holden D, Terwilliger G, Duque A, Arellano J, van Dyck C, Bateman R, Xie Z, Nairn A, Arnsten A. Chronic GCPII (glutamate‐carboxypeptidase‐II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaques. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12431. PMID: 37915375, PMCID: PMC10617575, DOI: 10.1002/trc2.12431.
- Datta D, Perone I, Morozov Y, Arellano J, Duque A, Rakic P, van Dyck C, Arnsten A. Localization of PDE4D, HCN1 channels, and mGluR3 in rhesus macaque entorhinal cortex may confer vulnerability in Alzheimer’s disease. Cerebral Cortex 2023, 33: 11501-11516. PMID: 37874022, PMCID: PMC10724870, DOI: 10.1093/cercor/bhad382.
- Miller A, Mecca A, Sharp E, van Dyck C, O'Dell R. Hearing Loss is Associated with Faster Cognitive Decline but not Diagnostic Conversion in the ADNI Cohort. American Journal Of Geriatric Psychiatry 2023, 31: e19-e20. DOI: 10.1016/j.jagp.2023.02.027.
- Silva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Varma P, Toyonaga T, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET. American Journal Of Geriatric Psychiatry 2023, 32: 17-28. PMID: 37673749, PMCID: PMC10840732, DOI: 10.1016/j.jagp.2023.08.002.
- Sperling R, Donohue M, Raman R, Rafii M, Johnson K, Masters C, van Dyck C, Iwatsubo T, Marshall G, Yaari R, Mancini M, Holdridge K, Case M, Sims J, Aisen P. Trial of Solanezumab in Preclinical Alzheimer’s Disease. New England Journal Of Medicine 2023, 389: 1096-1107. PMID: 37458272, PMCID: PMC10559996, DOI: 10.1056/nejmoa2305032.
- O'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Ni G, Chupak A, Zhao W, Salardini E, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease. NeuroImage Clinical 2023, 39: 103457. PMID: 37422964, PMCID: PMC10338149, DOI: 10.1016/j.nicl.2023.103457.
- Lanctôt K, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg P, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Padala K, Herrmann N. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. American Journal Of Geriatric Psychiatry 2023, 31: 1077-1087. PMID: 37385898, PMCID: PMC10765607, DOI: 10.1016/j.jagp.2023.06.002.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. 557. Nanoscale Imaging of pT217-Tau in Aged Rhesus Macaque: Trans-Synaptic Propagation and Seeding of Tau Pathology in Entorhinal Cortex. Biological Psychiatry 2023, 93: s319. DOI: 10.1016/j.biopsych.2023.02.797.
- van Dyck C, Sabbagh M, Cohen S. Lecanemab in Early Alzheimer's Disease. Reply. New England Journal Of Medicine 2023, 388: 1631-1632. PMID: 37099355, DOI: 10.1056/nejmc2301380.
- Lanctôt K, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2023, 35: 664-672. PMID: 37066690, PMCID: PMC10579450, DOI: 10.1017/s1041610223000327.
- Chen C, McCullough A, Gordon B, Joseph-Mathurin N, Flores S, McKay N, Hobbs D, Hornbeck R, Fagan A, Cruchaga C, Goate A, Perrin R, Wang G, Li Y, Shi X, Xiong C, Pontecorvo M, Klein G, Su Y, Klunk W, Jack C, Koeppe R, Snider B, Berman S, Roberson E, Brosch J, Surti G, Jiménez-Velázquez I, Galasko D, Honig L, Brooks W, Clarnette R, Wallon D, Dubois B, Pariente J, Pasquier F, Sanchez-Valle R, Shcherbinin S, Higgins I, Tunali I, Masters C, van Dyck C, Masellis M, Hsiung R, Gauthier S, Salloway S, Clifford D, Mills S, Supnet-Bell C, McDade E, Bateman R, Benzinger T. Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 50: 2669-2682. PMID: 37017737, PMCID: PMC10330155, DOI: 10.1007/s00259-023-06209-0.
- Van Dyck C, O'Dell R, Mecca A. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12388. PMID: 37187779, PMCID: PMC10175943, DOI: 10.1002/trc2.12388.
- Lanctôt K, Sankhe K, Perin J, Herrmann N, Brawman-Mintzer O, Lerner A, Mintzer J, Padala P, Rosenberg P, Shade D, van Dyck C, Porsteinsson A. Correlation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial. American Journal Of Geriatric Psychiatry 2023, 31: s100-s101. DOI: 10.1016/j.jagp.2022.12.146.
- Mah E, Lanctôt K, Chen Q, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Mintzer J, Herrmann N. Cost Consequence Analysis of ADMET 2. American Journal Of Geriatric Psychiatry 2023, 31: s101. DOI: 10.1016/j.jagp.2022.12.147.
- Sabbagh M, van Dyck C. Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke. New England Journal Of Medicine 2023, 388: 480-480. PMID: 36599073, DOI: 10.1056/nejmc2215907.
- Mallinckrodt C, Tian Y, Aisen P, Barkhof F, Cohen S, Dent G, Hansson O, Harrison K, Iwatsubo T, Mummery C, Muralidharan K, Nestorov I, Nisenbaum L, Rajagovindan R, von Hehn C, van Dyck C, Vellas B, Wu S, Zhu Y, Sandrock A, Chen T, Budd Haeberlein S. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab. The Journal Of Prevention Of Alzheimer's Disease 2023, 10: 171-177. PMID: 36946443, DOI: 10.14283/jpad.2023.6.
- Cohen S, van Dyck C, Gee M, Doherty T, Kanekiyo M, Dhadda S, Li D, Hersch S, Irizarry M, Kramer L. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer’s Disease. The Journal Of Prevention Of Alzheimer's Disease 2023, 10: 771-777. PMID: 37874099, DOI: 10.14283/jpad.2023.123.
- O'Dell R, Mecca A, Waszak J, Sharp E, Chen M, Naganawa M, Toyonaga T, Lu Y, Chupak A, Cooper E, Lam J, Miller A, Waldner E, Weibley H, Zhao Y, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Association of synaptic density and glucose metabolism with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB‐J and [18F]FDG. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.062595.
- Salardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065162.
- Salardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer’s Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065064.
- Gordon B, Flores S, Dincer A, Keefe S, McKay N, Hobbs D, Wisch J, Hornbeck R, Franklin E, Jack C, Koeppe R, Xiong C, McDade E, van Dyck C, Klein G, Pariente J, Bateman R, Morris J, Perrin R, Benzinger T. Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063285.
- Pandey K, Waybright L, Duong D, Malagise E, Blennow K, Zetterberg H, Mecca A, van Dyck C, Caggiano A, Seyfried N, Hamby M. CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer’s disease patients from the SPARC clinical trial. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.068166.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. Nanoscale imaging of pT217‐tau in aged rhesus macaque: Trans‐synaptic propagation and seeding of tau pathology in entorhinal cortex. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.064956.
- Lanctôt K, Perin J, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.066932.
- Gordon B, Flores S, Dincer A, Keefe S, McKay N, Hobbs D, Wisch J, Hornbeck R, Franklin E, Jack C, Koeppe R, Xiong C, van Dyck C, McDade E, Klein G, Pariente J, Bateman R, Morris J, Ances B, Benzinger T, Perrin R. Examining the effects of sex and age on tau PET binding in the absence of beta‐amyloid pathology. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.061090.
- Villa L, Colic L, Kim J, Sankar A, Goldman D, Lessing B, Pittman B, Alexopoulos G, van Dyck C, Blumberg H. Aging of the brain in bipolar disorder: Illness- and onset-related effects in cortical thickness and subcortical gray matter volume. Journal Of Affective Disorders 2022, 323: 875-883. PMID: 36526112, PMCID: PMC9839524, DOI: 10.1016/j.jad.2022.12.026.
- van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer L, Iwatsubo T. Lecanemab in Early Alzheimer’s Disease. New England Journal Of Medicine 2022, 388: 9-21. PMID: 36449413, DOI: 10.1056/nejmoa2212948.
- Wilson E, Young C, Ramos Benitez J, Swarovski M, Feinstein I, Vandijck M, Le Guen Y, Kasireddy N, Shahid M, Corso N, Wang Q, Kennedy G, Trelle A, Lind B, Channappa D, Belnap M, Ramirez V, Skylar-Scott I, Younes K, Yutsis M, Le Bastard N, Quinn J, van Dyck C, Nairn A, Fredericks C, Tian L, Kerchner G, Montine T, Sha S, Davidzon G, Henderson V, Longo F, Greicius M, Wagner A, Wyss-Coray T, Poston K, Mormino E, Andreasson K. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease. Alzheimer's Research & Therapy 2022, 14: 172. PMID: 36371232, PMCID: PMC9652927, DOI: 10.1186/s13195-022-01116-2.
- Kelly K, O'Dell R, Toyonaga T, Barcelos N, Gelernter J, Varma P, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. P95. Cortical Amyloid Burden is Associated With Basal Forebrain but Not Medial Temporal Lobe Atrophy in Adults at Varying APOE ɛ4 Risk for Alzheimer’s Disease. Biological Psychiatry 2022, 91: s125-s126. DOI: 10.1016/j.biopsych.2022.02.329.
- Kelly K, Toyonaga T, Zhao W, Barcelos N, Gelernter J, Varma P, Nabulsi N, Wyk B, Huang Y, Carson R, van Dyck C, Mecca A. The relationship between cortical amyloid burden and basal forebrain volume in adults at varying APOE ?4 risk for Alzheimer's disease. American Journal Of Geriatric Psychiatry 2022, 30: s25. DOI: 10.1016/j.jagp.2022.01.301.
- Silva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PET. American Journal Of Geriatric Psychiatry 2022, 30: s26. DOI: 10.1016/j.jagp.2022.01.303.
- O'Dell R, van Dyck C, Mecca A. All that's Amnestic Isn't Alzheimer's: a Clinical Case Report of an Alzheimer's disease-like Amnestic Syndrome with Incongruent Biomarkers. American Journal Of Geriatric Psychiatry 2022, 30: s24. DOI: 10.1016/j.jagp.2022.01.295.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. Subcellular localization of PDE4D and HCN1 in rhesus macaque entorhinal cortex layer II: Signature of vulnerability in Alzheimer’s disease. Alzheimer's & Dementia 2022, 17 DOI: 10.1002/alz.054671.
- Budd Haeberlein S, Aisen P, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery C, Muralidharan K, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck C, Vellas B, Wu S, Zhu Y, Sandrock A. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. The Journal Of Prevention Of Alzheimer's Disease 2022, 9: 197-210. PMID: 35542991, DOI: 10.14283/jpad.2022.30.
- Chaudhary S, Zhornitsky S, Chao H, van Dyck C, Li C. Hypothalamic Functional Connectivity and Apathy in People with Alzheimer's Disease and Cognitively Normal Healthy Controls. Journal Of Alzheimer's Disease 2022, 90: 1615-1628. PMID: 36314209, PMCID: PMC10064487, DOI: 10.3233/jad-220708.
- Mecca A, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Zhao W, Nabulsi N, Brinkmalm A, Kvartsberg H, Schöll M, Arnsten A, Huang Y, Blennow K, Zetterberg H, Carson R, van Dyck C, Nilsson J. Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: Biomarkers of synaptic density in Alzheimer’s disease. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054831.
- Mintzer J, Scherer R, Drye L, Lanctôt K, Rosenberg P, Herrmann N, Padala P, Brawman‐Mintzer O, Lerner A, Levey A, Porsteinsson A, van Dyck C. Apathy in Dementia Methylphenidate Trial 2 (ADMET2): Results of a phase III, placebo‐controlled, double‐blind, 6‐month, multi‐center, randomized clinical trial. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.051489.
- Chen C, McCullough A, Gordon B, Joseph‐Mathurin N, Wang G, Li Y, Xiong C, Pontecorvo M, Klein G, Shcherbinin S, Higgins I, Masters C, Clifford D, van Dyck C, Masellis M, Hsiung G, Gauthier S, Bateman R, McDade E, Salloway S, Benzinger T. [11C]PiB and [18F]AV45 PET radiotracers show different rates of amyloid‐β clearance. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.056094.
- Baker L, Cotman C, Morrison R, Katula J, Chmelo E, Hodge H, Johnson C, Kipperman S, Matthews G, Bennett D, Mason J, LaCroix A, van Dyck C, Okonkwo O, Tam S, Fairchild J, Li C, Welsh‐Bohmer K, Feldman H, Group T. EXERT: Impact of COVID‐19 on retention and intervention delivery of a large multisite exercise trial in adults with MCI. Alzheimer's & Dementia 2021, 17: e056518. PMCID: PMC9011773, DOI: 10.1002/alz.056518.
- van Dyck C, Sharp E, O'Dell R, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A. Synaptic density is associated with cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐J. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054213.
- Zhou B, Wang R, Chen M, Mecca A, O’Dell R, Van Dyck C, Carson R, Duncan J, Liu C. Synthesizing Multi-tracer PET Images for Alzheimer’s Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial Network. 2021, 12906: 34-43. DOI: 10.1007/978-3-030-87231-1_4.
- O'Dell R, Mecca A, Sharp E, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Carson R, Arnsten A, van Dyck C. Synaptic Loss is Associated With Cognitive Impairment in Early Alzheimer’s Disease: A PET Imaging Study With [11C]UCB-J. Biological Psychiatry 2021, 89: s107-s108. DOI: 10.1016/j.biopsych.2021.02.276.
- Pathak GA, Wendt FR, Levey DF, Mecca AP, van Dyck CH, Gelernter J, Polimanti R. Pleiotropic effects of telomere length loci with brain morphology and brain tissue expression. Human Molecular Genetics 2021, 30: 1360-1370. PMID: 33831179, PMCID: PMC8255129, DOI: 10.1093/hmg/ddab102.
- Villa L, Colic L, Sankar A, Goldman D, Lessing B, Alexopoulos G, van Dyck C, Blumberg H. Age-Related Brain Structure Differences, by Age of Onset, in Older Adults with Bipolar Disorder. American Journal Of Geriatric Psychiatry 2021, 29: s26. DOI: 10.1016/j.jagp.2021.01.019.
- O'Dell R, Mecca A, Chen M, Naganawa M, Toyonaga T, Lu Y, Godek T, Harris J, Bartlett H, Banks E, Kominek V, Zhao W, Nabulsi N, Ropchan J, Ye Y, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C. Association of Aß deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. American Journal Of Geriatric Psychiatry 2021, 29: s37-s40. DOI: 10.1016/j.jagp.2021.01.034.
- Sharp E, O'Dell R, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A, van Dyck C. Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. American Journal Of Geriatric Psychiatry 2021, 29: s119-s120. DOI: 10.1016/j.jagp.2021.01.114.
- Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's diseaseO'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Banks E, Bartlett H, Harris J, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease. American Journal Of Geriatric Psychiatry 2021, 29: s47-s48. DOI: 10.1016/j.jagp.2021.01.041.
- Salardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Laltoo E, Savoia S, O'Dell R, Harris J, Godek T, Nabulsi N, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037792.
- Mecca A, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Harris J, Bartlett H, Banks E, Kominek V, Nabulsi N, Najafzadeh S, Wyk B, Brinkmalm A, Kvartsberg H, Schöll M, Arnsten A, Huang Y, Blennow K, Zetterberg H, Carson R, van Dyck C. Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.044211.
- Salardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Laltoo E, Savoia S, O'Dell R, Harris J, Godek T, Nabulsi N, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. 11C‐PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043584.
- O'Dell R, Mecca A, Chen M, Godek T, Harris J, Bartlett H, Banks E, Kominek V, Zhao W, Naganawa M, Toyonaga T, Lu Y, Nabulsi N, Ropchan J, Ye Y, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. Association between cerebral amyloid accumulation and synaptic density in Alzheimer’s disease: A multitracer PET study. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043631.
- Fang X, Mecca A, Naganawa M, O'Dell R, Chen M, van Dyck C, Carson R. ICA‐derived sources of synaptic density PET ([11C]UCB‐J) relate to cognitive impairment severity in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.041197.
- Mecca A, O'Dell R, Chen M, Naganawa M, Toyonaga T, Godek T, Harris J, Bartlett H, Zhao W, Gallezot J, Nabulsi N, Ropchan J, Ye Y, Wyk B, Arnsten A, Huang Y, Carson R, van Dyck C. In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037791.
- O'Dell R, Naganawa M, Toyonaga T, Young J, Dahal R, Singh E, Waheed A, Banks E, Harris J, Chen M, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Validation of a simplified tissue‐to‐reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer’s disease using [11C]UCB‐J PET. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.045928.
- LaCroix A, van Dyck C, Okonkwo O, Tam S, Fairchild J, Li C, Welsh‐Bohmer K, Shadyab A, Matthews G, Bennett D, Shadyab A, Schafer K, Morrison R, Kipperman S, Tan D, Feldman H, Cotman C, Baker L, Group E. Recruitment for a multi‐site randomized controlled trial of aerobic exercise for older adults with amnestic mild cognitive impairment: The EXERT trial. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.044658.
- Salloway S, Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Farlow M, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, van Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Baudler M, Delmar P, Doody R, Fontoura P, Kerchner G, Team D. Gantenerumab in‐depth outcomes. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.038049.
- Datta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. The calcium‐containing smooth endoplasmic reticulum is a focus of risk factors for early‐ and late‐onset Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.047651.
- Farlow M, Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Salloway S, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, van Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Andersen S, Holdridge K, Mintun M, Sims J, Yaari R, Team D. Solanezumab in‐depth outcomes. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.038028.
- Leslie S, Datta D, Wang M, van Dyck C, Arnsten A, Nairn A. Biochemical characterization of age‐related calcium‐cAMP‐PKA signaling dysregulation and its effect on tau pathology in rhesus monkey cortex. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.042017.
- van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanctôt KL, Rosenberg PB. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. American Journal Of Geriatric Psychiatry 2020, 29: 51-62. PMID: 32461027, PMCID: PMC7641967, DOI: 10.1016/j.jagp.2020.04.026.
- O'Dell R, Mecca A, Chen M, Godek T, Harris J, Bartlett H, Zhao W, Naganawa M, Toyonaga T, Lu Y, Nabulsi N, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDY. American Journal Of Geriatric Psychiatry 2020, 28: s123-s124. DOI: 10.1016/j.jagp.2020.01.153.
- Mecca AP, McDonald JW, Michalak HR, Godek TA, Harris JE, Pugh EA, Kemp EC, Chen MK, Salardini A, Nabulsi NB, Lim K, Huang Y, Carson RE, Strittmatter SM, van Dyck CH. PET imaging of mGluR5 in Alzheimer’s disease. Alzheimer's Research & Therapy 2020, 12: 15. PMID: 31954399, PMCID: PMC6969979, DOI: 10.1186/s13195-020-0582-0.
- van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. JAMA Neurology 2019, 76: 1219-1229. PMID: 31329216, PMCID: PMC6646979, DOI: 10.1001/jamaneurol.2019.2050.
- Datta D, Morozov Y, van Dyck C, Arnsten A. F164. Ultrastructural Localization of Classical Complement Cascade Signaling Protein C1q in Rhesus Macaque Dorsolateral Prefrontal Cortex. Biological Psychiatry 2019, 85: s276-s277. DOI: 10.1016/j.biopsych.2019.03.701.
- Gupta M, O'Dell R, Gelernter J, Carson R, van Dyck C, Mecca A. ASSOCIATION BETWEEN ODOR IDENTIFICATION AND REGIONAL GRAY MATTER IN EARLY PRECLINICAL ALZHEIMER'S DISEASE. American Journal Of Geriatric Psychiatry 2019, 27: s143-s144. DOI: 10.1016/j.jagp.2019.01.098.
- O'Dell R, Gupta M, Gelernter J, Carson R, van Dyck C, Mecca A. REGION-SPECIFIC ATROPHY AS MEASURED BY CORTICAL GRAY MATTER VOLUME IS ASSOCIATED WITH BOTH REGIONAL AND TOTAL CORTICAL AMYLOID-BETA BURDEN IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE. American Journal Of Geriatric Psychiatry 2019, 27: s145-s146. DOI: 10.1016/j.jagp.2019.01.100.
- Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurology 2018, 75: 1215-1224. PMID: 30014145, PMCID: PMC6233853, DOI: 10.1001/jamaneurol.2018.1836.
- Barcelos NM, Van Ness PH, Wagner AF, MacAvoy MG, Mecca AP, Anderson GM, Trentalange M, Hawkins KA, Sano M, Arnsten AFT, van Dyck CH. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. Neurobiology Of Aging 2018, 70: 117-124. PMID: 30007160, PMCID: PMC6503670, DOI: 10.1016/j.neurobiolaging.2018.05.033.
- Mecca A, Chen M, Naganawa M, Finnema S, Toyonaga T, Lin S, McDonald J, Michalak H, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Poster Number: NR 14 Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials? American Journal Of Geriatric Psychiatry 2018, 26: s145-s146. DOI: 10.1016/j.jagp.2018.01.176.
- van Dyck CH. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise. Biological Psychiatry 2017, 83: 311-319. PMID: 28967385, PMCID: PMC5767539, DOI: 10.1016/j.biopsych.2017.08.010.
- Lanctot K, Scherer R, Li A, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J. [O1–01–06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS. Alzheimer's & Dementia 2017, 13: p184-p184. DOI: 10.1016/j.jalz.2017.07.038.
- Mecca A, Rogers K, Jacobs Z, McDonald J, Michalak H, DellaGioia N, Nabulsi N, Matuskey D, Esterlis I, Carson R, van Dyck C. Poster Number: EI 39 Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18F]FPEB and PET. American Journal Of Geriatric Psychiatry 2017, 25: s96-s97. DOI: 10.1016/j.jagp.2017.01.110.
- van Dyck C, Mecca A, Wang S, Barcelos N, Planeta-Wilson B, Gelernter J, Van Ness P, Carson R. P3‐143: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first‐degree relatives at varying ApoE4 risk for Alzheimer's disease. Alzheimer's & Dementia 2015, 11: p680-p681. DOI: 10.1016/j.jalz.2015.06.1011.
- van Dyck C, Mecca A, Wang S, Barcelos N, Planeta-Wilson B, Gelernter J, Van Ness P, Carson R. IC‐P‐101: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first‐degree relatives at varying ApoE4 risk for Alzheimer's disease. Alzheimer's & Dementia 2015, 11: p69-p69. DOI: 10.1016/j.jalz.2015.06.123.
- Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC, Rosenberg BJ, Sekine-Konno T, Varma P, Chen K, Koleske AJ, Reiman EM, Strittmatter SM, van Dyck CH. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimer's Research & Therapy 2015, 7: 35. PMID: 25874001, PMCID: PMC4396171, DOI: 10.1186/s13195-015-0119-0.
- Istace A, Bracoud L, Berman R, Luo F, Roche F, Salloway S, van Dyck C, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Ferris S, Grill J, Gouttard S, Schaerer J, Hayes W, Kaplita S, Belaroussi B, Yu H, Cedarbaum J, Feldman H, Pachai C, Coric V. IC‐P‐108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. Alzheimer's & Dementia 2014, 10: p60-p61. DOI: 10.1016/j.jalz.2014.05.114.
- Coric V, Salloway S, van Dyck C, Kerselaers W, Kaplita S, Curtis C, Ross J, Richter R, Andreasen N, Brody M, Sharma S, Cedarbaum J, Berman R. P1–343: A phase II study of the gamma‐secretase inhibitor avagacestat (BMS‐708163) in predementia Alzheimer's disease. Alzheimer's & Dementia 2013, 9: p283-p283. DOI: 10.1016/j.jalz.2013.05.569.
- van Dyck C, Barcelos N, Brück A, Planeta‐Wilson B, Gelernter J, Carson R. IC‐O1‐03: Amyloid burden and neuropsychological performance in presymptomatic first‐degree relatives at varying APOE‐ɛ4 risk for Alzheimer's disease. Alzheimer's & Dementia 2012, 8: p5-p5. DOI: 10.1016/j.jalz.2012.05.018.
- Bracoud L, Coric V, van Dyck C, Andreasen N, Ross J, Brody M, Curtis C, Belaroussi B, Yu H, Kaplita S, Feldman H, Pachai C, Berman R. IC‐P‐140: Baseline clinical scores and volumetric MRI parameters across subjects randomized in mild‐to‐moderate (BMS CN156‐013) and predementia (BMS CN156‐018) Alzheimer's disease clinical trials of avagacestat. Alzheimer's & Dementia 2012, 8: p73-p74. DOI: 10.1016/j.jalz.2012.05.174.
- Bracoud L, Coric V, van Dyck C, Andreasen N, Ross J, Brody M, Curtis C, Belaroussi B, Yu H, Kaplita S, Feldman H, Pachai C, Berman R. P2‐414: Baseline clinical scores and volumetric MRI parameters across subjects randomized in mild‐to‐moderate (BMS CN156‐013) and predementia (BMS CN156‐018) Alzheimer's disease clinical trials of avagacestat. Alzheimer's & Dementia 2012, 8: p409-p409. DOI: 10.1016/j.jalz.2012.05.2039.
- Farlow M, Arnold SE, van Dyck C, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's & Dementia 2012, 8: 261-271. PMID: 22672770, DOI: 10.1016/j.jalz.2011.09.224.
- van Dyck C, Brück A, Barcelos N, Planeta‐Wilson B, Benincasa A, MacAvoy M, Ding Y, Gelernter J, Carson R. IC‐P‐106: Amyloid‐ß burden and neuropsychological test performance in cognitively normal first‐degree relatives at varying genetic risk for Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s51-s52. DOI: 10.1016/j.jalz.2011.05.071.
- van Dyck C, Brück A, Barcelos N, Planeta‐Wilson B, Benincasa A, MacAvoy M, Ding Y, Gelernter J, Carson R. P1‐387: Amyloid‐ß burden and neuropsychological test performance in cognitively normal first‐degree relatives at varying genetic risk for Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s236-s236. DOI: 10.1016/j.jalz.2011.05.668.
- Salloway S, Porsteinsson A, Sperling R, Keren R, van Dyck C, Tariot P, Gilman S, Crans G, Hernandez R, Quinn G, Bairu M, Cedarbaum J, Pastrak A, Abushakra S. P2‐499: Safety and efficacy results of a phase II randomized, placebo‐controlled, dose‐ranging study of elnd005 (scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s472-s472. DOI: 10.1016/j.jalz.2011.05.1371.
- Salloway S, Coric V, Brody M, Andreasen N, van Dyck C, Soininen H, Thein S, Shiovitz T, Kumar S, Pilcher G, Colby S, Rollin L, Feldman H, Berman R. O4‐06‐08: Safety and tolerability of BMS‐708163 in a phase II study in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s695-s696. DOI: 10.1016/j.jalz.2011.05.2011.
- Porsteinsson A, Sperling R, Salloway S, Keren R, van Dyck C, Tariot P, Arnold D, Crans G, Hernandez R, Liang E, Bairu M, Cedarbaum J, Pastrak A, Abushakra S. O4‐06‐07: Imaging and cerebrospinal fluid biomarker results of a phase II dose‐ranging study of ELND005 (Scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2011, 7: s695-s695. DOI: 10.1016/j.jalz.2011.05.2010.
- Ding Y, Planeta-Wilson B, Hannestad J, Gallezot J, Lin S, Williams W, Quinlan D, Carson R, van Dyck C. The role of norepinephrine transporter in attention deficit hyperactivity disorder. NeuroImage 2010, 52: s108. DOI: 10.1016/j.neuroimage.2010.04.087.
- Mitsis EM, Reech KM, Bois F, Tamagnan GD, MacAvoy MG, Seibyl JP, Staley JK, van Dyck CH. 123I-5-IA-85380 SPECT Imaging of Nicotinic Receptors in Alzheimer Disease and Mild Cognitive Impairment. Journal Of Nuclear Medicine 2009, 50: 1455-1463. PMID: 19690024, DOI: 10.2967/jnumed.109.064030.
- Santhosh L, Estok KM, Vogel RS, Tamagnan GD, Baldwin RM, Mitsis EM, MacAvoy MG, Staley JK, van Dyck CH. Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET. Psychiatry Research 2009, 173: 212-217. PMID: 19682865, DOI: 10.1016/j.pscychresns.2009.03.007.
- Harrington C, Sawchak S, Chiang C, Davies J, Saunders A, Irizarry M, Zvartau‐Hind M, van Dyck C, Gold M. P4‐299: Effects Of Rosiglitazone‐extended Release As Adjunctive Therapy To Acetylcholinesterase Inhibitors Over 48 Weeks On Cognition In Apoe4‐stratified Subjects With Mild‐to‐moderate Alzheimer's Disease. Alzheimer's & Dementia 2009, 5: e17-e18. DOI: 10.1016/j.jalz.2009.07.079.
- Mitsis EM, Cosgrove KP, Staley JK, Bois F, Frohlich EB, Tamagnan GD, Estok KM, Seibyl JP, van Dyck CH. Age-related decline in nicotinic receptor availability with [123I]5-IA-85380 SPECT. Neurobiology Of Aging 2008, 30: 1490-1497. PMID: 18242781, PMCID: PMC3523217, DOI: 10.1016/j.neurobiolaging.2007.12.008.
- Batis J, Esterlis I, Bois F, Cosgrove K, Stiklus S, Kloczynski T, McKee S, Jatlow P, O'Malley S, Seibyl J, Tamagnan G, Van Dyck C, Staley J. SPECT imaging of [123I]5-IA-85380 binding to beta2-nicotinic acetylcholine receptors in healthy smokers: Assessment of nondisplaceable uptake. NeuroImage 2008, 41: t175. DOI: 10.1016/j.neuroimage.2008.04.142.
- Batis J, Yang B, Cosgrove K, Bois F, Esterlis I, Stiklus S, Kloczynski T, Perry E, Seibyl J, Tamagnan G, Van Dyck C, Gelernter J, Staley J. Single nucleotide polymorphisms of ANKK1 and CHRNA4: Influence on nicotinic acetylcholine receptor availability in nonsmokers measured using [123I]5-IA-85380 SPECT. NeuroImage 2008, 41: t174. DOI: 10.1016/j.neuroimage.2008.04.141.
- van Dyck CH, Avery RA, MacAvoy MG, Marek KL, Quinlan DM, Baldwin RM, Seibyl JP, Innis RB, Arnsten AF. Striatal dopamine transporters correlate with simple reaction time in elderly subjects. Neurobiology Of Aging 2007, 29: 1237-1246. PMID: 17363113, PMCID: PMC3523216, DOI: 10.1016/j.neurobiolaging.2007.02.012.
- Zdanys KF, Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, Garman KS, Tampi RR, Gelernter J, van Dyck CH. Apolipoprotein E ɛ4 Allele Increases Risk for Psychotic Symptoms in Alzheimer's Disease. Neuropsychopharmacology 2006, 32: 171-179. PMID: 16841077, DOI: 10.1038/sj.npp.1301148.
- Staley J, Tellioglu T, Bois F, Palazzo C, McGuire-Schwartz N, Cosgrove K, van Dyck C, Tamagnan G, Seibyl J, Krystal J, D'Souza D. [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers. NeuroImage 2006, 31: t154. DOI: 10.1016/j.neuroimage.2006.04.137.
- Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiology Of Aging 2005, 27: 1416-1424. PMID: 16182410, DOI: 10.1016/j.neurobiolaging.2005.08.002.
- Petersen R, Thomas R, Grundman M, Bennett D, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck C, Thal L. [O1‐04‐04]: Operational criteria for patient recruitment in trials of mild cognitive impairment. Alzheimer's & Dementia 2005, 1: s87-s87. DOI: 10.1016/j.jalz.2005.06.303.
- KUGAYA A, EPPERSON C, van DYCK C, FUJITA M, INNIS R. Dr. Kugaya and Colleagues Reply. American Journal Of Psychiatry 2004, 161: 2136-a-2136. DOI: 10.1176/appi.ajp.161.11.2136-a.
- van Dyck C, Cummings J, Schmitt F, Graham S, Olin J, Jin J, Tariot P. P4.028 Functional and behavioral effects of memantinein Alzheimer's disease. European Neuropsychopharmacology 2004, 14: s334-s335. DOI: 10.1016/s0924-977x(04)80452-8.
- Cummings J, van Dyck C, Schmitt F, Graham S, Olin J, Jin J, Tariot P. P1-315 Functional and behavioral effects of memantine in Alzheimer's disease. Neurobiology Of Aging 2004, 25: s186. DOI: 10.1016/s0197-4580(04)80628-6.
- Karlawish J, James B, Kim S, Knopman D, van Dyck C, Marson D. P2-393 Alzheimer's disease patient and caregiver attitudes about proxy informed consent. Neurobiology Of Aging 2004, 25: s345. DOI: 10.1016/s0197-4580(04)81135-7.
- Martinez D, Gelernter J, Abi-Dargham A, van Dyck C, Kegeles L, Innis R, Laruelle M. The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans. Neuropsychopharmacology 2001, 24: 553-560. PMID: 11282255, DOI: 10.1016/s0893-133x(00)00216-5.
- Staley J, Van Dyck C, Tan P, Tikriti M, Ramsby Q, Klump H, Ng C, Garg P, Soufer R, Baldwin R, Innis R. Comparison of [18F]altanserin and [18F]deuteroaltanserin for PET imaging of serotonin2A receptors in baboon brain: pharmacological studies. Nuclear Medicine And Biology 2001, 28: 271-279. PMID: 11323237, DOI: 10.1016/s0969-8051(00)00212-2.
- Soares J, van Dyck C, Tan P, Zoghbi S, Garg P, Soufer R, Baldwin R, Fujita M, Staley J, Fu X, Amici L, Seibyl J, Innis R. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin. Psychiatry Research 2001, 106: 81-93. PMID: 11306248, DOI: 10.1016/s0925-4927(01)00071-3.
- van Dyck C. Neuroimaging in alzheimer’s disease: Relevance for treatment. Current Psychiatry Reports 2001, 3: 13-19. PMID: 11177754, DOI: 10.1007/s11920-001-0066-2.
- van Dyck C, Soares J, Tan P, Staley J, Baldwin R, Amici L, Fu X, Garg P, Seibyl J, Charney D, Innis R. Equilibrium modeling of 5-ht2a receptors with [18f]deuteroaltanserin and pet: feasibility of a constant infusion paradigm. Nuclear Medicine And Biology 2000, 27: 715-722. PMID: 11150702, DOI: 10.1016/s0969-8051(00)00160-8.
- Avery R, Franowicz J, Studholme C, van Dyck C, Arnsten A. The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Cortex of Monkeys Performing a Spatial Working Memory Task. Neuropsychopharmacology 2000, 23: 240-249. PMID: 10942848, DOI: 10.1016/s0893-133x(00)00111-1.
- Mulnard R, Cotman C, Kawas C, van Dyck C, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Study L. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial. Obstetrical & Gynecological Survey 2000, 55: 439-440. DOI: 10.1097/00006254-200007000-00021.
- van Dyck C, Malison R, Seibyl J, Laruelle M, Klumpp H, Zoghbi S, Baldwin R, Innis R. Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT. Neurobiology Of Aging 2000, 21: 497-501. PMID: 10924762, DOI: 10.1016/s0197-4580(00)00152-4.
- van Dyck C, Basso M, Yang J, Half L, MacAvoy M, Varma P, Gelernter J. Apolipoprotein E ε4 allele is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiology Of Aging 2000, 21: 39. DOI: 10.1016/s0197-4580(00)82852-3.
- Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D’Souza D, Krystal J, Seibyl J, Baldwin R, Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT. Biological Psychiatry 2000, 47: 371-379. PMID: 10704949, DOI: 10.1016/s0006-3223(99)00257-7.
- Mulnard R, Cotman C, Kawas C, van Dyck C, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal L, Study F. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial. JAMA 2000, 283: 1007-1015. PMID: 10697060, DOI: 10.1001/jama.283.8.1007.
- van Dyck CH, Newhouse P, Falk WE, Mattes JA. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. Archives Of General Psychiatry 2000, 57: 157-64. PMID: 10665618, DOI: 10.1001/archpsyc.57.2.157.
- Verhoeff N, Soares J, D’Souza C, Gil R, Degen K, Abi-Dargham A, Zoghbi S, Fujita M, Rajeevan N, Seibyl J, Krystal J, van Dyck C, Charney D, Innis R. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Research 1999, 91: 163-173. PMID: 10641580, DOI: 10.1016/s0925-4927(99)00027-x.
- Malison R, Price L, Berman R, van Dyck C, Pelton G, Carpenter L, Sanacora G, Owens M, Nemeroff C, Rajeevan N, Baldwin R, Seibyl J, Innis R, Charney D. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry 1998, 44: 1090-1098. PMID: 9836013, DOI: 10.1016/s0006-3223(98)00272-8.
- Gelernter J, Van Dyck C, van Kammen D, Malison R, Price L, Cubells J, Berman R, Charney D, Heninger G. Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. American Journal Of Medical Genetics 1997, 74: 497-500. PMID: 9342199, DOI: 10.1002/(sici)1096-8628(19970919)74:5<497::aid-ajmg8>3.0.co;2-l.
- van Dyck C, Lin C, Robinson R, Cellar J, Smith E, Nelson J, Arnsten A, Hoffer P. The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer’s disease. Psychopharmacology 1997, 132: 217-226. PMID: 9292621, DOI: 10.1007/s002130050339.
- Arnsten A, Lin C, Van Dyck C, Stanhope K. The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiology Of Aging 1997, 18: 21-28. PMID: 8983029, DOI: 10.1016/s0197-4580(96)00162-5.
- Laruelle M, Abi-Dargham A, van Dyck C, Krystal J, Charney D, Innis R. 208. Increased striatal dopamine release in drug free schizophrenic subjects. Biological Psychiatry 1996, 39: 560. DOI: 10.1016/0006-3223(96)84153-9.
- Laruelle M, Abi-Dargham A, Gil R, van Dyck C, Erdos J, D'Souza D, Rosenblatt W, McCance-Katz E, Zea-Ponce Y, Zoghbi S, Baldwin R, Hoffer P, Krystal J, Charney D, Innis R. SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia. Schizophrenia Research 1996, 18: 198-199. DOI: 10.1016/0920-9964(96)85619-2.
- van Dyck C, Seibyl J, Stubbs J, Zoghbi S, Wisniewski G, Baldwin R, Zea-Ponce Y, Charney D, Hoffer P, Innis R. Human biodistribution and dosimetry of the SPECT D2 dopamine receptor radioligand [123I]IBF. Nuclear Medicine And Biology 1996, 23: 9-16. PMID: 9004921, DOI: 10.1016/0969-8051(95)02003-9.
- van Dyck C, Rosen M, Thomas H, McMahon T, Wallace E, O'Connor P, Sullivan M, Krystal J, Hoffer P, Woods S, Kosten T. SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry Research 1994, 55: 181-191. PMID: 7701033, DOI: 10.1016/0925-4927(94)90013-2.
- Laruelle M, Al-Tikriti M, Van Dyck C, Zoghbi S, Zea-Ponce Y, Baldwin R, Charney D, Hoffer P, Innis R. D-amphetamine displacement of [123I]IBF equilibrium binding in primates: A new paradigm to investigate D-amphetamine induced dopamine release. Schizophrenia Research 1993, 9: 201. DOI: 10.1016/0920-9964(93)90423-g.
- Rosen M, Bridge T, O'Malley S, Pearsall H, Martini B, O'Connor P, Brett‐Smith H, Thomas H, Van Dyck C, Woods S, Kosten T. Peptide T Treatment of Cognitive Impairment in HIV‐Positive Intravenous Drug Users. American Journal On Addictions 1992, 1: 332-338. DOI: 10.1111/j.1521-0391.1992.tb00359.x.
- Rosen M, Bridge T, O'Malley S, Pearsall H, Martini B, O'Connor P, Brett-Smith H, Thomas H, van Dyck C, Woods S, Kosten T. Peptide T Treatment of Cognitive Impairment in HIV-Positive Intravenous Drug Users. American Journal On Addictions 1992, 1: 332-338. DOI: 10.3109/10550499208993153.
Departments and Programs
Locations
1
1 of 2
- Yale Alzheimer's Disease Research Unit1 Church StreetSte 8th FloorNew Haven, CT 06510
- Adler Geriatric Assessment Center874 Howard AvenueNew Haven, CT 06519
1
1 of 2
- Yale Alzheimer's Disease Research Unit1 Church StreetSte 8th FloorNew Haven, CT 06510
- Adler Geriatric Assessment Center874 Howard AvenueNew Haven, CT 06519